Axsome Therapeutics Launches SYMBRAVO for Migraine Relief

Axsome Therapeutics ( (AXSM) ) has issued an update.

On June 10, 2025, Axsome Therapeutics announced the commercial availability of SYMBRAVO®, a novel treatment for acute migraine with or without aura in adults. SYMBRAVO offers a multi-mechanistic approach, providing rapid and sustained pain relief, and is supported by comprehensive patient services. This launch addresses a significant unmet need in migraine treatment, potentially benefiting millions of individuals dissatisfied with existing options.

The most recent analyst rating on (AXSM) stock is a Buy with a $175.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.

Spark’s Take on AXSM Stock

According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.

Axsome Therapeutics shows promising growth prospects with strong revenue increases and pipeline advancements. However, financial challenges, including ongoing losses and cash flow issues, weigh heavily on the overall score. The recent loan agreement and positive technical indicators provide some support, but regulatory hurdles and profitability concerns remain significant risks.

To see Spark’s full report on AXSM stock, click here.

More about Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. The company is known for its innovative treatments and is committed to improving the lives of patients with CNS conditions.

Average Trading Volume: 711,357

Technical Sentiment Signal: Buy

Current Market Cap: $5.51B

Learn more about AXSM stock on TipRanks’ Stock Analysis page.